University of Alabama at Birmingham
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Alabama at Birmingham sits in the top decile of US sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count).
University of Alabama at Birmingham: 1,160 sponsored US clinical trials, 216 recruiting.
University of Alabama at Birmingham sponsors 1,160 registered US clinical trials on ClinicalTrials.gov, 216 of them currently recruiting, and 723 completed. 97 of these trials are in Phase 3-4 (later-stage) and 259 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
University of Alabama at Birmingham ranks in the top decile of sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
723 of 812 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,160 total, page 6 of 24
The Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture
NCT04809714
Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers
NCT04633811
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
NCT04975555
Reducing Vertical Transmission of Hepatitis B in Africa
NCT04704024
Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers
NCT04333745
Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis
NCT04964466
Gout in the ED and Improving Research Participation
NCT04075903
Exclusive Enteral Nutrition in Preterm Neonates
NCT04337710
Using Early Time Restricted Feeding and Timed Light Therapy to Improve Glycemic Control in Adults With Type 2 Diabetes
NCT04155619
Dietary Oxalate and Innate Immunity in Kidney Stone Disease
NCT04051346
A Comparison of Side Access Mucosal Releasing Incision (SAMRI) and Sulcular Tunnel Access to Treat Gingival Recession.
NCT04179448
Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors
NCT04469569
Health Disparities on the Labor Floor
NCT04633824
Prenatal Behavioral Intervention to Prevent Maternal Cytomegalovirus (CMV) in Pregnancy
NCT04615715
Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT
NCT04318886
NTX-301 in MDS/AML
NCT04167917
Racial Differences in Circadian and Sleep Mechanisms for Nicotine Dependence, Craving, and Withdrawal
NCT03968900
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
NCT04177940
Early Protein Supplementation in Extremely Preterm Infants Fed Human Milk
NCT04325308
Renal Metabolism of Glycolate to Oxalate
NCT04437225
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
NCT04000880
Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma
NCT04165941
Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors
NCT04088708
Neuroinflammation After Myocardial Infarction - Imaging Substudy
NCT03968445
Trial of C134 in Patients With Recurrent GBM
NCT03657576
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
NCT03368729
Influence of Obesity on Endogenous Oxalate Synthesis
NCT03704350
Impact of Glaucoma and Visual Field Loss on Life Space
NCT03673644
Serial Assessment of Body Fat Accrual in Very Preterm Infants
NCT03575897
Comparing Inflammatory Markers in Patients With and Without Depression With Chronic Periodontitis
NCT03553095
Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study
NCT03442101
Project BIPAMS: Behavioral Intervention for Physical Activity in Multiple Sclerosis
NCT03490240
Pulmonary Function Using Non-invasive Forced Oscillometry
NCT03346343
RAD 1601: EDGE Radiosurgery for Intractable Essential Tremor and Tremor-Dominant Parkinson's Disease
NCT03305588
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (EDSPD Protocol)
NCT02997020
Dietary Oxalate and Immune Cell Function
NCT03877276
High Resolution Micro OCT Imaging
NCT03256773
RAD 1501: A Trial of Virtual Cone Trigeminal Neuralgia Radiosurgery
NCT02708810
Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors
NCT00959140
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
NCT02062827
Vascular Reparative Mechanism in Diabetes
NCT02119689
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
NCT01196936
MEDBRIDGE-Guided NCM/CHW Post-Discharge Support for High-Risk T2D Patients
NCT07599852
Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism
NCT05114980
Efficacy of Different Disinfection Technologies in Molar Non-Surgical Retreatment
NCT07469150
Comparative Effectiveness in the Management of Irreversible Pulpitis
NCT04922229
Monitoring Blood Pressure at Home and Pharmacy Telehealth
NCT07623291
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
NCT05676489
Feasibility and Acceptability of Three Component Intervention for the Heart Failure Care for Rural Dwelling Participants
NCT07103239
Remote Intervention to Prevent Overdose
NCT07128485
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 129 |
| Phase 2 | 130 |
| Phase 3 | 25 |
| Phase 4 | 72 |
Therapeutic Areas
What is open in the University of Alabama at Birmingham pipeline
216 recruiting of 1,160 indexed (19% open); 723 completed (62%).
Phase mix: 97 late (III/IV) vs 259 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Alabama at Birmingham: open-pipeline peers nationwide
Peers matched on 1,160 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,160 trials (± recruiting share)
- NYU Langone Health · 1,164 trials · 17% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 19% open enrollment (± trial volume)
- University of Minnesota · 19% recruiting · 966 trials
- Mclean Hospital · 19% recruiting · 140 trials
- Children's Hospital Medical Center, Cincinnati · 19% recruiting · 571 trials
- Arkansas Children's Hospital Research Institute · 19% recruiting · 97 trials
Related
What to do with this University of Alabama at Birmingham page
1,160 registered trials is a research-attention snapshot, not an endorsement of University of Alabama at Birmingham or any single study.
- 216 of University of Alabama at Birmingham's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of Alabama at Birmingham studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Alabama at Birmingham pipeline card: 1,160 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.